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Abstract
Background: The FOLFOX regimen, i.e., folinic acid (FOL), fluorouracil (F) and oxaliplatin (OX), is a drug cocktail that
is used to treat gastric and colorectal cancers. Despite the concomitant improvements in response rate, duration of
response and patient survival, reports of serious toxic pulmonary side effects have progressively emerged.
Case presentation: We describe a patient who was treated with FOLFOX as an adjuvant to a rectosigmoidal resection
of a rectosigmoidal carcinoma and who developed respiratory insufficiency requiring mechanical ventilation. Computed
tomography (CT) imaging and open lung biopsy findings were compatible with interstitial pneumonia (IP). She received
multimodal combination treatment (acetylcysteine, corticosteroids, immune globulins and cyclophosphamide) and survived.
We performed a systematic literature search and reviewed all 45 reported cases of FOLFOX-related lung toxicity and/or
pulmonary fibrosis for their clinical characteristics and their outcomes related to therapy.
Conclusions:We found that for the 45 cases with available data, the median age was 70 years, and the male–female ratio
was 3.5: 1. In the patients exhibiting only mild respiratory symptoms, discontinuation of the culprit drug (oxaliplatin) resulted
in a 100% regression of the symptoms. However the prognosis of the respiratory insufficient patient proved to be grim:
death occurred in 76.9% of the cases despite conventional treatment with corticosteroids. We therefore urge oncologists
and critical care specialists not to limit their interventions to the discontinuation of chemotherapy, artificial ventilation,
corticosteroids and glutathione replenishment and to consider the gradual introduction of additional immune-modulating
agents whenever life-threatening respiratory symptoms in oxaliplatin-treated patients do not subside; all the more so
considering the fact that our analysis showed that every patient who survived intubation and mechanical ventilation
experienced a full clinical recovery.
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Background
Since the middle of the previous century, 5-
fluorouracil (5-FU) has been the cornerstone in the
treatment of colorectal cancer. The initial addition of
folinic acid (leucovorin) and subsequent addition of
oxaliplatin (OX) resulted in improved response rates,
longer remissions and an increase in patient survival
[1, 2]. Subsequently, the combination of folinic acid,
5-fluorouracil and oxaliplatin, i.e., the so-called FOL-
FOX regimen, became a well-established treatment
for colorectal malignancy either as in monotherapy or
as an adjuvant to surgery [1]. With the widespread
use of this triple chemotherapeutic combination ther-
apy, reports of increased toxicity (e.g., peripheral
neuropathy, neutropenia, thrombocytopenia, vomiting)
compared with the 5-FU/leucovorin treatment
emerged [3]. Additionally, interstitial lung disease has
been reported. In the majority of cases, the noxious
pulmonary effects occur rather late in the course of
therapy [4–9], although there have been exceptions to
this rule [10–14]. Although pulmonary toxicity in
conjunction with FOLFOX therapy is uncommon (≤
1.5%) [15], it can be lethal despite the immediate
discontinuation of the chemotherapeutic drugs and
the initiation of immunotherapy (i.e., corticosteroids).
Indirect arguments designating oxaliplatin as the
causative pulmonary toxic agent can be found in
more than one publication [4, 7, 12, 14, 16–19].
We describe a patient with profound pulmonary
toxicity secondary to FOLFOX who was successfully
treated with a combination of acetylcysteine,
corticosteroids, immune globulins and cyclophospha-
mide. Additionally we reviewed all other reports of
similar cases.
Case presentation
A 49-year-old non-smoking female patient, who
received a diagnosis of rectosigmoidal carcinoma 4
months prior and was treated with (laparoscopic)
rectosigmoidal resection and adjuvant FOLFOX
chemotherapy, was admitted to the hospital due to
progressive dyspnoea approximately 3 weeks after the
sixth chemotherapy session. CT examination of the
lungs revealed extensive abnormalities in both lungs
with diffuse ground glass abnormalities in both the
upper (Fig. 1a) and lower lobes (Fig. 1b) and areas of
consolidation at the level of the lower lobes (Fig. 1b).
Antibiotics were empirically prescribed (moxifloxacin)
from day one. Hypoxic respiratory insufficiency arose
and necessitated intubation 1 week after admission.
Immediately thereafter, she was referred to our
university hospital. On admission to our intensive
care unit (ICU), 70% oxygen (PEEP 8 cm H20) was
needed to prevent frank hypoxemia. The serum white
blood cell count amounted to 19 × 10 9/L (the
normal value is up to 10 × 10 9/L). Predominantly,
neutrophils (78.8%, 14.97 × 10 9/L) and to a lesser
extent lymphocytes (16.3%, 3.10 × 10 9/L), were
present. There was no peripheral eosinophilia. The C-
reactive protein (CRP) level was low (1.2 mg/dl), and
there were no biochemical signs of other organ failure
(i.e., serum creatinine 0.55 mg/dl).
Fig. 1 axial CT images of the chest in the lung window setting at the levels of the upper lobes (images in a, c and e) and the lower lobes (images in b, d
and f). CT examination at the time of diagnosis revealed extensive abnormalities in both lungs with diffuse ground glass abnormalities in both the upper
(a) and lower lobes (b). Associated areas of consolidation at the lower lobe level were present. Follow-up images 11 weeks after multimodal therapy for
ILD revealed a good resolution of the ground glass abnormalities and consolidation with only minor parenchymal changes in the upper lobes, some small
foci of ground glass abnormalities and some parenchymal bands (c). In the lower lobes, the nodular area (d asterisk) was consistent with loculated
postoperative fluid due to the open-lung biopsy. The most recent examination more than 4 years after the event (e, f) showed no abnormalities
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Shortly after admittance to our ICU, a bronchoalveolar
lavage (BAL) was performed in the right middle lobe
and revealed a white blood cell count of 44/m3 that
mostly consisted of neutrophils (90%) in addition to 4%
lymphocytes, 6% macrophages and no eosinophils, which
suggested infectious lung disease or acute diffuse lung
injury [20]. However, no microorganisms (e.g., (myco)-
bacteria, moulds, fungi, or viruses (entero-, rhino-, para-
influenza, adeno-, herpes simplex, or cytomegalovirus))
were detected. PCR on the BAL fluid for herpes simplex,
cytomegalovirus, Epstein-Barr virus, Chlamydia pneu-
moniae, Mycoplasma pneumoniae and Bordetella per-
tussis also proved negative. Additional histopathological
examination of the lavage liquid did not reveal malignant
cells. There was no family history of interstitial lung dis-
ease (ILD), and there were no coexisting medical condi-
tions that favoured the development of ILD. Moreover,
there had been no occupational exposure to pulmonary
toxins and no prior use of potential ILD-causing drugs
(e.g., bleomycin, busulphan, gemcitabine, mitomycin,
paclitaxel, docetaxel, nitrofurantoin, amiodarone), with
the exception of the FOLFOX chemotherapy.
Given the proof of the absence of pulmonary infection,
at 48 h after admission, high-dose corticosteroids
(methylprednisolone 4 × 250 mg per day) were adminis-
tered intravenously (IV) over 5 consecutive days
followed by a tapering scheme. This therapy was initi-
ated while considering the possibility of an autoimmune
disease or chemotherapy-related pulmonary toxicity
[21]. Meanwhile, IV acetylcysteine (1800 mg per day)
had been administered from day one in our hospital with
the initial intention of preventing contrast-induced
nephropathy in this CT-scanned patient.
In view of the fact that screening for autoimmune and
systemic diseases (e.g., anti-nuclear antibodies, anti-
neutrophil cytoplasmatic antibodies, complement fac-
tors, circulating immune complexes, lupus anticoagu-
lant, immune globulin dosage, retinal fundoscopy)
revealed no aberrations, and based on the absence of a
favourable respiratory evolution after 14 days of therapy,
a surgical (open) lung biopsy (right middle lobe) and a
tracheotomy were performed.
An initial quick examination of the lung biopsy frag-
ments revealed an interstitial pattern of disease with
widening of the alveolar septa. While awaiting further
microscopic characterization, immune globulins
(Sandoglobulin 0.4 g/kg) were administered intraven-
ously during a five-day period in an attempt to reduce
the pulmonary inflammation that led to fibrosis [22–24].
Approximately a fortnight later, a single dose of cyclo-
phosphamide (10.5 mg/kg = 1000 mg, Endoxan, Baxter,
Braine-l-Alleud Walloon Brabant, Lessines Hainaut,
Belgium) was administered due to the persistent need
for ventilatory support and the possibility of an
unspecified immunological process. The intravenous
administration of acetylcysteine was continued. After
these therapeutic interventions, the oxygen demand
gradually fell. The definite histopathological findings val-
idated the presence of on-going damage of the alveolar
epithelium with evolving pulmonary fibrosis. Thickened
alveolar septa with lymphocytic inflammatory infiltrate
and fibrosis and an exudate in the alveolar lumina lined
with reactive cuboid pneumocytes were present. There
were no arguments for concomitant vasculitis, infection
or malignancy (Fig. 2).
The interstitial pattern on chest X-ray and follow-up
CT gradually dissolved. A follow-up CT-scan 13 weeks
after admittance to our ICU revealed a good resolution
of the ground glass abnormalities and consolidation with
only minor residual parenchymal changes in the upper
lobes (Fig. 1c).
The patient remained dependent upon mechanical
ventilation until day 80 due to intercurrent ventilator-
associated pulmonary infections that were treated with
broad-spectrum antibiotics, acute bilateral pulmonary
embolism, critical illness myopathy (secondary to the
glucocorticoid treatment) and polyneuropathy (electro-
myographically confirmed), all of which contributed to
the general neuromuscular weakness and failure to wean
from mechanical ventilation.
On day 101, she was referred to the department of re-
spiratory medicine for further care still receiving oral
methylprednisolone at a dosage of 20 mg per day and
acetylcysteine in a daily dosage of 1200 mg.
She left the hospital 8 months after admission and
resumed work 1 year after discharge. She remained
under medical supervision and, in a diagnostic work
up for evolving carcinoembryonic antigen, underwent
computed tomography of the lungs more than 4 years
later. No residual pulmonary abnormalities were
found (Fig. 1 e-f ).
Methods
A systematic literature search was performed in PubMed
for all publications (case reports and case series) regard-
ing FOLFOX-related pulmonary toxicity with or without
pulmonary fibrosis, respiratory insufficiency, intubation
and artificial ventilation. To reduce/eliminate the chance
of bias, we excluded all reported cases that were not
treated solely with FOLFOX (e.g., FOLFOX/bevacizu-
mab) or not solely attributable to FOLFOX. The corre-
sponding authors of the reports that did not mention
the ventilation or intubation statuses of their patients
were contacted by e-mail or telephone to provide this
information because it was our aim to describe and
compare treatment strategies in the dramatic cases, i.e.,
the respiratory insufficient, intubated patients. Forty-five
cases were identified [4–19, 25–39]. The data were
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analyzed using Student’s t-tests. Values of p < 0.05 were
considered statistically significant.
Results
Interstitial lung disease associated with FOLFOX therapy
seems to be a global problem. Physicians on nearly every
continent (Table 1) have published reports regarding this
topic. Including our own, there are currently 45 reports
about FOLFOX-related pulmonary toxicity, including 18
from Asia, 16 from Europe, 5 from North America, 3
from South America and 3 from Oceania.
An overview of all of the reported FOLFOX-related
pulmonary disease cases (Table 1) revealed that there
seems to be an overwhelming male preponderance (male
(M) 35/45 = 77,8%; female (F) 10/45 = 22,2%). Although
the overall incidence of digestive cancer is higher in men
[40–42], the incidence of oxaliplatin-related non-
pulmonary toxic symptoms (e.g., neurotoxicity) is higher
in women [43], which thus leaves the question of a pos-
sible increase in male gender-related pulmonary toxicity
unresolved.
The mean age of all patients who developed pulmon-
ary toxicity was 67.6 years (Y), with mean ages of 68.7 Y
for the males and 63.9 Y for the women.
On average, ILD attributable to FOLFOX occurred
after a median of 8 cycles of FOLFOX therapy (range 1–
22 cycles) and a mean dose of 729.8 mg/m2 OX (range
85–1200 mg/m2, median 700 mg/m2). The men who
developed pulmonary toxicity did so after a mean of 8.2
therapy cycles (range 1–22 cycles, median 8 cycles) and
a mean OX dose of 738.3 mg/m2 (range 85–1716 mg/
m2, median 732.5 mg/m2). The women who developed
ILD did so after a mean of 7.6 cycles (range 2–12 cycles,
median 7 cycles) and a mean OX dose of 701 mg/m2
(range 170–1200 mg/m2, median 630 mg/m2). These dif-
ferences in mean age, number of cycles and mean dose
were not significant between the men and women (all
Ps > 0.5).
Five of the 45 patients (11.1%) with evidence of ILD
on imaging studies received no other therapy other than
the discontinuation of FOLFOX. These patients only
exhibited mild symptoms (Table 2). None of these
patients died. The other 40 patients (40/45 = 88.9%)
with more marked symptoms were treated with corti-
costeroids, and 36 (36/40 = 90%) of these patients
were treated with corticosteroids as a monotherapy
(36/45 = 80% of the total study population). Twenty
of the 36 patients treated with corticosteroids as
monotherapy (55.6%) exhibited improvement, and 16
(44.4%) of these patients died.
In the group of patients who exhibited improvement
after treatment with corticosteroids as monotherapy, the
mean number of FOLFOX therapy cycles was 6.95
(range 1–12 cycles, median 7 cycles). These patients had
been treated with a mean OX dose of 630.35 mg/m2
(range 85–1200 mg/m2, median 690 mg/m2). Despite
the fact that steroids have a much shorter half life in
women than in men [44], five of the 7 female patients
(71.4%) who were treated with corticosteroids as mono-
therapy exhibited improvement as opposed to only 15 of
the 29 male patients (51.7%). This difference might be
Fig. 2 lung tissue (day 14, open-lung biopsy, staining Hematoxylin
Eosin) exhibiting a pattern compatible with on-going damage of the
alveolar epithelium with evolving pulmonary fibrosis. a magnification
37×: histology (wedge biopsy) revealing lung tissue with a disturbed
architecture. The alveolar septa are thickened in a non-specific interstitial
pneumonia (NSIP) pattern with lymphocytic inflammatory infiltrate and
fibrosis. b magnification 185×: the alveolar lumina exhibit the presence
of an exudate. c Magnification 380×: reactive cuboid pneumocytes line
the alveolar lumina. This picture is consistent with interstitial pneumonitis
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explained by the fact that females exhibit a greater sensi-
tivity to corticosteroids [44].
The patients who died in this group had received a
mean 9.56 cycles of therapy (range 4–22, median 8.5
cycles) and a mean OX dose of 812.25 mg/m2 (median
732.5 mg/m2).
Three of the 4 (75%) patients who were treated with a
multimodal therapy regimen exhibited improvement.
One patient was treated with a combination of cortico-
steroids and acetylcysteine, another was treated with a
combination of corticosteroids and cyclophosphamide.
One patient who was treated with a combination of cor-
ticosteroids, cyclophosphamide and immune globulins
died. Prior to the FOLFOX treatment, he was diagnosed
with Wegener’s disease with lung involvement, which
probably contributed to the severity of the progression
of ILD and his demise [10]. Our own patient was treated
with a combination of corticosteroids, acetylcysteine,
immune globulins and cyclophosphamide and exhibited
improvement.
Information regarding intubation or not was avail-
able for 38 of the 45 patients (84.4%). Twenty-five of
these patients did not receive mechanical ventilation
(25/38 = 65.8%): 23 of them did not require it (23/
25 = 92%), two of them were not intubated due to
patient or family refusal.
The patients who were intubated had been treated
with a mean OX dose of 742.92 mg/m2 (range 85–
1716 mg/m2, median 680 mg/m2). The patients who
were not intubated had been treated with a mean OX
dose of 740.83 mg/m2 (range 100–1200 mg/m2, median
750 mg/m2).
Ten of the 13 patients (10/13 = 76.9%) who were intu-
bated died. They had been treated with a mean OX dose
of 821.10 mg/m2 (range 340–1716 mg/m2, median
722.5 mg/m2). The intubated patients who survived had
received a mean OX dose of 482.33 mg/m2 (range 85–
782 mg/m2, median 580 mg/m2).
Nine of the 10 intubated patients who died (90%) were
treated with corticosteroids as monotherapy. The tenth
intubated patient who died was the one with Wegener’s
disease.
Two of the intubated patients who survived (2/
3 = 66.67%) were treated with corticosteroids as mono-
therapy. The third patient who survived was our patient
and was treated with acetylcysteine, corticosteroids,
immune globulins and cyclophosphamide. All of the
patients who had been intubated and survived developed
complete resolution of their respiratory symptoms.
Seventeen out of the 45 (37.8%) patients died. The
patients who died had been treated (mean of 9.24
episodes) with a mean dose of OX dose of 784. 47 mg/m2
(range 340–1716 mg/m2, median 700 mg/m2). The
patients who survived had received a mean OX dose
of 695.44 mg/m2 (range 85–1200 mg/m2, median
700 mg/m2) over a mean of 7 therapy cycles. Again,
these differences were not significant.
In summary, we found that the discontinuation of the
precipitating drug resulted in a 100% regression of the
symptoms in the patients whose respiration was not too
strongly affected, and we demonstrated that intubation
heralded death in the majority of cases even with
corticosteroid treatment.
Discussion
Interstitial lung disease has diverse origins (e.g., auto-
immune or systemic disease, exposure to drugs or herbs,
infection, radiation, inhaled organic and inorganic sub-
stances, the late phase of the adult respiratory distress
syndrome, cryptogenic) [45, 46] and often leads to death.
The diagnosis of a drug-induced lung disorder is con-
sidered when diagnostic algorithms have excluded all
Table 2 Clinical characteristics of patients with FOLFOX therapy related pulmonary disease treated with discontinuation of chemotherapy
Reference Patient
Gender/Age
Preexisting lung disease with the





Gagnadoux F/60 None No Cough, progressive
dyspnea on exertion
None FEV1 1.980 L (90%)
TLC 4.207 L (90%)
DLCO 4.4 ml/mmHg/
min (59%)
Ruiz Casado M/67 CT: some signs of pulmonary
fibrosis in the basal portions
NA None None NA
Wilcox F/77 None No Dry cough, dyspnea
on exertion
None Normal lung volumes
DLCO 9.3 ml/mmHg/
min (54%)





None FVC 2.26 L (95%)
FEV 1 1.46 L (92%)
DLCO 10,8 ml/min/
mmHg (109%)
Basyigit M/60 None Ex-smoker 14
pack years
Dyspnea on exertion None NA
FEV1 Forced Expiratory Volume In One Second, FVC Forced Vital Capacity, TLC Total Lung Capacity, DLCO Diffusing Capacity of carbon monoxide, NA Not Available
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other potential aetiologies and when a distinct temporal
association between exposure to the drug(s) and the de-
velopment of respiratory complaints can be established
[47]. In our patient, the respiratory symptoms arose after
the 6th chemotherapy session, were rapidly progressive
in nature, and were without microbial, autoimmune or
environmental explanation. No infectious causes trigger-
ing the clinical picture were identified, although the high
neutrophil count in the bronchoalveolar lavage fluid was
initially strongly suggestive of microbial disease. In retro-
spect, we found that this finding was also compatible
with drug-induced lung disease [20]. In view of the fact
that an autoimmune disease could not be diagnosed, the
administration of FOLFOX was considered to be the
probable and most plausible cause of the biopsy-proven
interstitial pneumonitis. Similar histological findings
have been reported in three other cases of FOLFOX-
related ILD [10, 32, 39].
To which of the three components of the FOLFOX
regimen should the development of ILD be attributed?
Thus far, there have been no reports linking folinic acid
(leucovorin) in monotherapy to pulmonary toxicity.
Five-fluorouracil is a thymidilate synthase inhibitor
whose antimetabolite properties are enhanced by folates.
It is one of the most frequently used chemotherapeutic
agents and is applied in mono- and combined therapy
for various solid malignancies of the head, neck, breast,
lungs, gastrointestinal tract, prostate and bladder.
Known side effects include alopecia, stomatitis, emesis,
coronary spasms, hand-foot syndrome, diarrhoea and
myelosuppression [48, 49]. There has only been one
(Japanese) report of pulmonary toxicity accompanying
the administration of 5-FU as monotherapy [50]. Oxali-
platin is a third-generation platinum derivative (diami-
nocyclohexane, containing platinum) that blocks DNA
replication and transcription through the induction of
intrastrand or interstrand lesions and DNA protein cross
links [51]. Oxaliplatin is active against breast, gastric and
colon cancers, renal cell carcinoma, sarcoma and
cisplatin-resistant cell lines and tumour models
including lung, ovarian, cervix, colon and leukaemia cell
lines [51]. Known side effects include alopecia,
peripheral sensory neuropathy (limb dysesthesia or
paresthesia), haematological abnormalities (anaemia,
thrombocytopenia, neutropenia), electrolyte distur-
bances (hyponatraemia, kalaemia), hepatocellular
injury, nausea and vomiting, ototoxicity and laryngeal
dysesthesia [6, 52, 53]. An important indirect argument
pointing in the direction of oxaliplatin as “the” pulmon-
ary toxicity-inducing culprit lies in the observation that
respiratory symptoms present during FOLFOX therapy
do not recur after rechallenge with a 5-FU- and
leucovorin-containing but oxaliplatin-deprived chemo-
therapy cocktail [4, 7, 12, 14, 16–19].
When ILD is thought to be secondary to a chemical
insult, discontinuation of the causative agent should be
the first therapeutic intervention. Although sufficient for
some, not all patients will experience improvement or
full recovery after the cessation of the culprit compound.
In our patient, the FOLFOX administration had already
been discontinued, and acetylcysteine (supplying gluta-
thione) was administered from day one in our hospital.
Given that arguments linking oxaliplatin administra-
tion to glutathione depletion exist [30, 32], it seemed
logical to continue glutathione supplementation
because this molecule plays an important role in
protecting the lungs against oxidative damage, which
is a possible and probable contributing factor to the
emergence of interstitial pneumonitis and subsequent
evolution to pulmonary fibrosis.
Accounting for the severity of the illness, corticoster-
oid therapy, which is a well-established therapy modality,
was initiated shortly after disease onset. Because no
favourable respiratory evolution over a 14-day steroid
course was observed, and no autoimmune disease had
been diagnosed in the meantime, intravenous immune
globulins (IVIgs) were given in an attempt to reduce the
deposition of excessive amounts of extracellular proteins
(particularly collagen-I) in the lung and thus prohibit the
progression of the lung fibrosis already observed in the
patient’s lung biopsy. These IVIgs were administered
over a five-day period. The rationale for this treatment
was found in experimental data that indicated that IVIgs
are capable of preventing and treating bleomycin-
induced pulmonary fibrosis in mice through the reduced
expression of collagen-I protein in the affected lungs
[23, 24]. Postulated mechanisms of this anti-fibrotic ac-
tion of IVIg include modulation of cytokine production,
inhibition of the complement reaction and inhibition of
the CD95 receptor (Fas) activity through the presence of
anti-Fas antibodies in IVIg [23, 54, 55]. Subsequently,
one dose of cyclophosphamide, a nitrogen mustard
alkylating and lymphocyte-modulating agent, was
administered. This immunosuppressive steroid-sparing
agent is used to treat autoimmune inflammatory
disorders and associated interstitial lung disease and is
frequently added to corticosteroid therapy to enhance
the clinical response due to the additional suppression
of immunoreactions that cause lung damage [56]. In our
patient, an intravenous pulse was administered because
at that moment, an unspecified immunological process
(possibly with vasculitis) leading to pulmonary fibrosis
seemed possible.
In our analysis of the 45 reported cases of FOLFOX-
related pulmonary disease, we found that the adminis-
tered treatments were variable in terms of the drugs
used and highly variable in terms of the durations and
dosages of the corticosteroids used. Hence, it was
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impossible to determine the exact contribution of each
individual drug or drug dosage to the recoveries of the
patients. Moreover, in some patients, ILD regression was
observed without special treatment but “merely” after
discontinuation of FOLFOX. The fact that our patient
exhibited no improvement after the withdrawal of the
causative agent and developed a full clinical and radio-
graphic recovery after the introduction of acetylcysteine,
corticosteroids, immune globulins and cyclophospha-
mide, led us to believe that a causal relationship between
this multimodal therapy and respiratory progress exists.
Considering the frequency with which FOLFOX ther-
apy is used worldwide, the reported incidence of ILD
seems extremely low. We wondered why this is. Are not
all cases of FOLFOX related pulmonary toxicity
reported, or are only a small number of people genetic-
ally or otherwise predisposed? Are there age, gender,
ethnic or geographical differences in the concentrations
of innate NO, glutathione or profibrotic agents (e.g., type
2 CD4-positive lymphocytes, CD40 receptor and ligand
interactions, interleukin-4, interleukin-10, interleukin–
13, Th3-type cytokine-transforming growth factor beta
1, and platelet-derived growth factor) [22–24] that con-
tribute to the development of pulmonary toxicity? Could
there be interindividual differences in oxaliplatin metab-
olism that lead to toxicity? Indeed, the biotransformation
of oxaliplatin leads to the formation of aquated platinum
forms in the blood. Three compounds can be found:
total platinum, free (ultrafiltrable) platinum, and erythro-
cyte platinum [57]. Platinum is rapidly cleared from the
plasma by renal elimination. However, what if the
erythrocyte platinum is not as harmless as generally
accepted but rather exhibits toxic effects in isolated
cases, and what if the clearance of erythrocyte platinum
is delayed in a minority of patients?
Conclusions
FOLFOX therapy related pulmonary toxicity is uncom-
mon but often lethal in respiratory insufficient patients.
We urge oncologists and critical care physicians not to
limit their interventions to the discontinuation of
chemotherapy, artificial ventilation, corticosteroid ther-
apy and glutathione replenishment and to consider the
gradual introduction of additional immune-modulating
agents (e.g., immune globulins and cyclophosphamide)
whenever life-threatening respiratory symptoms in
oxaliplatin-treated patients do not subside.
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